

## What we did and who participated

Conducted in 14 centers across 3 European countries (France, Germany and the UK).  
82 participants randomised & split into 2 groups.

### Group A

MDI with Insulin pen + isCGM\*  
41 participants

### Group B

MiniMed™ 780G system  
41 participants




### What we measured

HbA1c  
Time spent in glycemic ranges  
Severe hypoglycemic and diabetic ketoacidosis events  
Patient reported outcomes

# Adapting for ADAPT

The ADAPT study evaluates the impact of the MiniMed™ 780G system, compared to those on MDI+ isCGM in those living with type 1 diabetes that struggle to manage their glucose level.

## What we found



## What this means

### Proven clinical outcomes

The MiniMed™ 780G system shows improved clinical outcomes in people living with diabetes\*\*\* who are being treated with MDI + isCGM that struggle to manage their glucose level.

### Improved treatment satisfaction

A significant improvement in diabetes treatment satisfaction and fear of hypoglycemia when moving from MDI + isCGM to the MiniMed™ 780G system.

**The benefits of the MiniMed™ 780G system means better diabetes management, with less effort.**

**So you can spend more time on the things that matter to you.**

Published in The Lancet Diabetes & Endocrinology in 2022. Choudhary P. et al, Lancet Diabetes Endocrinol. 2022; 10 (10):720-731.

Information contained herein is not medical advice and should not be used as an alternative to speaking with your diabetes healthcare team. Discuss indications, contraindications, warnings, precautions, potential adverse events and any further information with your diabetes healthcare team.

EMEA-IPT-2200240 © Medtronic 2022. All rights reserved.

\* Intermittently Scanned Continuous Glucose Monitoring (isCGM)

\*\* vs. MDI + isCGM

The MiniMed™ 780G insulin pump is indicated for use by patients age 7-80 years living with Type 1 diabetes